Abstract: ObjectiveTo evaluate the expression of Hepatoma-derived growth factor (HDGF) and its clinical implication in breast cancer. MethodsThe expression of HDGF was detected by immunohistochemical method in 113 breast cancer and 32 breast hyperplasia tissues. At the same time, the expressions of human epidermal growth factor receptor 2 (HER -2), estrogen recaptor(ER) and progesterone (PR) were detected in breast cancer. The relationships between HDGF, ER, PR and HER-2 with clinical data were analyzed by multivariate analysis and Kaplan-Meier. Results Over-expression rate of HDGF in breast cancer tissues was higher than that in breast hyperplasia tissues（P<0.01）.There were no relationship between the expression of HDGF and age, pathological type, menostasis, ER and PR expression(P>0.05). However, HDGF expression was significantly correlation with tumor size, lymphnode metastasis, distant metastasis and HER-2 expression (P<0.01 or 0.05). Patients with low HDGF expression had a higher 5-year survival rates than those with HDGF over-expression (P<0.01). Multivariate analysis showed that HDGF was an important prognostic factor for breast cancer(RR=1.263，P<0.05). Conclusion The over-expression of HDGF was a novel biomarker involved in the poor prognosis of breast cancer.